Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Pharmaceutics Année : 2020

Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

Résumé

Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood–brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.
Fichier principal
Vignette du fichier
pharmaceutics-12-00937.pdf (681.01 Ko) Télécharger le fichier

Dates et versions

pasteur-03507944 , version 1 (03-01-2022)

Licence

Paternité

Identifiants

Citer

Elodie Pothin, Dominique Lesuisse, Pierre Lafaye. Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR. Pharmaceutics, 2020, 12 (10), pp.937. ⟨10.3390/pharmaceutics12100937⟩. ⟨pasteur-03507944⟩

Collections

PASTEUR CNRS
27 Consultations
190 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More